Some studies suggest that EGFR-TKIs might interfere with the proliferation and differentiation of type II alveolar epithelial cells (AT2) and inhibit epithelial cell repair following injury by targeting the EGFR signaling pathway in tumor tissues, leading to alveolar structural disruption and fibrosis (Ohmori et al., 2021). Here, EGFR is linked to neoplasm.